[1]张亚明.陀螺旋转式立体定向放射治疗局部晚期非小细胞肺癌的临床疗效[J].医学信息,2024,37(10):109-112.[doi:10.3969/j.issn.1006-1959.2024.10.022]
　ZHANG Ya-ming.Clinical Efficacy of Gyro Rotary Stereotactic Radiotherapy for Locally Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2024,37(10):109-112.[doi:10.3969/j.issn.1006-1959.2024.10.022]
点击复制

陀螺旋转式立体定向放射治疗局部晚期非小细胞肺癌的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年10期
页码:
109-112
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Clinical Efficacy of Gyro Rotary Stereotactic Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2024）10-0109-04
作者:
张亚明
（上饶市立医院放疗科，江西 上饶 334000）
Author(s):
ZHANG Ya-ming
(Department of Radiotherapy,Shangrao Municipal Hospital,Shangrao 334000,Jiangxi,China)
关键词:
非小细胞肺癌; 局部晚期; 陀螺旋转式立体定向放射治疗; 急性放射性肺炎
Keywords:
Non-small cell lung cancer; Locallyadvanced; Gyro rotary stereotactic radiotherapy; Acute radiation pneumonitis
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2024.10.022
文献标志码:
A
摘要:
目的 观察陀螺旋转式立体定向放射治疗（陀螺刀）治疗局部晚期非小细胞肺癌（NSCLC）的临床疗效。方法 以2021年1月-2023年3月上饶市立医院收治的60例局部晚期NSCLC患者为研究对象，依据随机数字表法分为对照组（30例）与观察组（30例）。对照组行常规放疗，观察组采用陀螺刀放疗，比较两组临床疗效、肿瘤标志物水平[鳞状细胞癌抗原（SCC）、癌胚抗原（CEA）、神经特异性烯醇化酶（NSE）]、Karnofsky功能状态量表（KPS）评分、美国东部肿瘤协作组（ECOG）活动状态评分、急性放射性肺炎（ARP）发生情况、不良反应。结果 观察组疾病控制率、客观缓解率高于对照组（P＜0.05）；两组治疗后SCC、CEA、NSE水平低于治疗前，且观察组SCC、CEA、NSE水平低于对照组（P＜0.05）；两组治疗后KPS评分高于治疗前，ECOG评分低于治疗前，且观察组KPS评分高于对照组，ECOG评分低于对照组（P＜0.05）；观察组ARP及不良反应发生率均小于对照组（P＜0.05）。结论 陀螺刀治疗局部晚期NSCLC效果肯定，可下调患者肿瘤标志物水平，改善其机体功能，降低ARP及不良反应的发生风险。
Abstract:
Objective To observe the clinical efficacy of gyro rotary stereotactic radiotherapy (gyro knife) in the treatment of locally advanced non-small cell lung cancer (NSCLC).Methods A total of 60 patients with locally advanced NSCLC admitted to Shangrao Municipal Hospital from January 2021 to March 2023 were divided into control group (30 patients) and observation group (30 patients) according to random number table method. The control group was treated with conventional radiotherapy, and the observation group was treated with gyro knife radiotherapy. The clinical efficacy, tumor marker levels [squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE)], Karnofsky Performance Scale (KPS) score, Eastern Cooperative Oncology Group (ECOG) activity status score, acute radiation pneumonitis (ARP) occurrence, and adverse reactions were compared between the two groups.Results The disease control rate and objective remission rate of the observation group were higher than those of the control group (P<0.05). After treatment, the levels of SCC, CEA and NSE in the two groups were lower than those before treatment, and the levels of SCC, CEA and NSE in the observation group were lower than those in the control group (P<0.05). The KPS score of the two groups after treatment was higher than that before treatment, and the ECOG score was lower than that before treatment, whilethe KPS score of the observation group was higher than that of the control group, and the ECOG score was lower than that of the control group (P<0.05). The incidence of ARP and adverse reactions in the observation group were lower than those in the control group (P<0.05).Conclusion Gyro knife is effective in the treatment of locally advanced NSCLC, which can down-regulate the level of tumor markers, improve the body function, and reduce the risk of ARP and adverse reactions.

参考文献/References:

[1]潘巍,陈惠,陈杰,等.粒-巨噬细胞集落刺激因子联合立体定向放疗治疗局部晚期或寡转移非小细胞肺癌的临床疗效观察[J].肿瘤学杂志,2023,29(2):106-110.[2]郝鹏,肖洪秋,李曈,等.手术、立体定向放射治疗与经皮穿刺消融治疗早期非小细胞肺癌效果的网状荟萃分析[J].临床与病理杂志,2022,42(8):1799-1814.[3]贾臻,张火俊,曹洋森,等.立体定向放疗联合化疗治疗中央型局部晚期非小细胞肺癌的疗效分析[J].现代肿瘤医学,2022,30(16):2942-2947.[4]江承川,刘先领.原发性肝癌陀螺刀治疗急性胃肠反应发生情况及危险因素分析[J].实用癌症杂志,2018,33(3):423-426.[5]董百强,王谨,徐裕金,等.142例早期非小细胞肺癌SBRT长期预后观察[J].中华放射肿瘤学杂志,2020,29(6):416-420.[6]中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华肿瘤杂志,2021,43(6):591-621.[7]赵洁,宁鹏,刘海明.埃克替尼片联合SBRT治疗对NSCLC血清肿瘤标志物的影响[J].河北医学,2021,27(4):697-700.[8]胡攀峰,郭文涨,黄婷婷,等.放疗与亚肺叶切除手术治疗早期非小细胞肺癌对患者生存的影响比较[J].中国肿瘤临床,2020,47(17):881-885.[9]李坪,孙晓南.体部立体定向放射治疗联合免疫检查点抑制剂在非小细胞肺癌中的应用[J].国际肿瘤学杂志,2022,49(2):116-120.[10]刘勋,吴喜福,陈云,等.顺铂联合立体定向体部放疗治疗晚期肺癌的疗效及对患者血清CYFRA21-1、DR70和肺功能的影响[J].现代生物医学进展,2019,19(24):4695-4698.[11]王启明,陆辉,许家玲.慈丹胶囊联合立体定向放疗同步GP方案化疗治疗局部晚期非小细胞肺癌研究[J].临床军医杂志,2018,46(11):1349-1351.[12]董妍,吴尚,杨建国.立体定向放射治疗非小细胞肺癌的疗效及对患者肺功能的影响研究[J].实用癌症杂志,2019,34(6):960-963.[13]Uhlig J,Ludwig JM,Goldberg SB,et al.Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study[J].Radiology,2018,289(3):862-870.[14]杨勇,苏国华,马力.陀螺刀立体定向放疗治疗早期非小细胞肺癌疗效评价及生存质量分析[J].中国临床医生杂志,2020,48(3):334-336.[15]周宁,欧阳志勇,张佳宁.γ射线体部立体定向放射治疗中晚期及复发性非小细胞肺癌39例临床观察[J].临床误诊误治,2018,31(10):13-16.[16]高玉伟,王杰,赵丽娟.立体定向精准放射治疗对老年非小细胞肺癌的临床疗效及对外周血CTCs和TK1的影响[J].中国医学装备,2021,18(10):110-115.[17]卜媛,王一安,李文峰.埃克替尼片联合体部立体定向放疗治疗晚期老年非小细胞肺癌的临床研究[J].中国临床药理学杂志,2018,34(11):1295-1297.[18]陈洁,刘德胜,贾钰铭,等.卡瑞利珠单抗联合立体定向体部放疗治疗晚期寡转移非小细胞肺癌的有效性和安全性研究[J].中国医师进修杂志,2022,45(6):554-559.[19]王海霞,单国用,刘兴安,等.立体定向放疗治疗非小细胞肺癌的免疫与肿瘤标志物变化及近期疗效影响因素[J].医学研究杂志,2018,47(2):119-123.[20]孙宇楠,段琼玉,牛楠,等.立体定向体部放疗联合或不联合化疗治疗≥5 cm的非小细胞肺癌的临床疗效及不良反应[J].现代肿瘤医学,2018,26(3):360-363.[21]朱瑶瑶,杨双燕,杨文艳,等.30例T2N0M0期非小细胞肺癌立体定向放射治疗临床疗效分析[J].中华放射医学与防护杂志,2019,39(12):904-909.[22]付金平,晋发,张秀伟,等.立体定向体部放射治疗早期非小细胞肺癌患者的疗效与预后因素分析[J].国际呼吸杂志,2019,39(23):1761-1765.[23]杨琼,王鹏.肺部直径＜5 cm病灶适形调强放疗及“陀螺刀”放疗的剂量分布比较[J].临床肺科杂志,2019,24(8):1489-1493.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(10):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(10):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(10):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(10):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(10):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(10):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(10):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(10):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(10):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(10):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01